Goldman Sachs analyst Chris Shibutani maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $54.00. The company’s shares closed last Tuesday at $51.50.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks.com, Shibutani is a 5-star analyst with an average return of 23.5% and a 46.8% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals, Inc., Entrada Therapeutics Inc, and Johnson & Johnson.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pfizer with a $60.13 average price target, representing a 18.7% upside. In a report issued on January 28, J.P. Morgan also maintained a Hold rating on the stock with a $57.00 price target.
See the top stocks recommended by analysts >>
Based on Pfizer’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $24.09 billion and net profit of $8.15 billion. In comparison, last year the company earned revenue of $10.28 billion and had a net profit of $1.47 billion.
Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PFE in relation to earlier this year. Most recently, in December 2021, Mikael Dolsten, the President R&D of PFE bought 177,304 shares for a total of $4,588,404.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pfizer Inc. develops, manufactures and sells healthcare products, including innovative medicines and vaccines. Its key focus areas include oncology, inflammation & immunology, rare disease, vaccines and internal medicine. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Read More on PFE:
- Lockheed Martin: Geopolitical Tensions Are a Tailwind
- Mizuho Securities Thinks Block’s Stock is Going to Recover
- Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sangamo Biosciences (SGMO) and Applied Genetic Technologies (AGTC)
- Is Peloton Stock a Buy Right Now? This Is What You Need to Know
- Needham Keeps a Hold Rating on Haemonetics (HAE)